Down-regulation by bucillamine of lamina propria leucocytes in the rat colitis model.
1. The efficacy of bucillamine has been reported in various inflammatory models. 2. In the present study, the effects of 2 weeks administration of bucillamine on hapten-induced experimental rat colitis were analysed. The gross morphological damage score was evaluated and the expression of CD4, CD8, CD11a, CD11b, CD25, CD54 and class II major histocompatibility complex (MHC) antigen was investigated by immunohistochemical methods. 3. Mean bodyweight was significantly increased in colitic rats given 750 micrograms bucillamine compared with colitic rats given vehicle (distilled water). Gross morphological damage was significantly less in colitic rats given 250 or 750 micrograms bucillamine compared with rats given vehicle. 4. Immunohistological studies revealed that CD4, CD11a, CD11b, CD54 and class II MHC antigen expression of infiltrating leucocytes was significantly lower in rat colonic mucosa treated with bucillamine. 5. From these findings, it appears that bucillamine may act through the down-regulation of the activation of lamina propria leucocytes in hapten-induced rat colitis.
Oshitani
N
N
Third Department of Internal Medicine, Osaka City University Medical School, Japan. robu@med.osaka-cu.ac.jp
Matsumoto
T
T
Nakamura
S
S
Arakawa
T
T
Kitano
A
A
Kuroki
T
T
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001485:Basement Membrane / Q000187:drug effects / Q000473:pathology; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D003545:Cysteine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects; D007962:Leukocytes / Q000187:drug effects* / Q000473:pathology*; D051381:Rats; D017208:Rats, Wistar
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003545:Cysteine; C026535:bucillamine